Eucure (beijing) Biopharma Co., Ltd

Researchers are running a phase 1 trial of YH004, an experimental drug given intravenously every three weeks, in people with advanced solid tumors or relapsed or refractory non-Hodgkin lymphoma. The main goal is to find out whether YH004 is safe and tolerable, and to determine th…

Researchers are testing an experimental antibody called YH004 in adults with advanced solid tumors or non-Hodgkin lymphoma that has come back or stopped responding to treatment. YH004 is designed to activate immune cells by targeting a protein called 4-1BB. The study gives YH004 …